Davie A P
Department of Cardiology, Western Infirmary, Glasgow, Scotland.
Pharmacoeconomics. 2000 Mar;17(3):237-43. doi: 10.2165/00019053-200017030-00002.
Economic analysis has been extensively used to guide the use of ACE inhibitors in chronic heart failure. More recently, it has been used to guide the use of ACE inhibitors after myocardial infarction. The results of major clinical trials leave us in no doubt that ACE inhibitors are useful in the treatment of patients after myocardial infarction. The results of economic analysis unanimously indicate that ACE inhibitors are cost effective when used to treat patients after myocardial infarction. Any comparison of the different treatment strategies available suggests that all are comparably cost effective and argues for the widest possible use of ACE inhibitors in this setting. The evidence suggests that, in this context as in so many others, ACE inhibitors remain under-utilized.
经济分析已被广泛用于指导血管紧张素转换酶（ACE）抑制剂在慢性心力衰竭中的应用。最近，它也被用于指导心肌梗死后ACE抑制剂的使用。主要临床试验的结果让我们确信，ACE抑制剂在治疗心肌梗死后的患者中是有用的。经济分析结果一致表明，ACE抑制剂用于治疗心肌梗死后的患者具有成本效益。对现有不同治疗策略的任何比较都表明，所有策略在成本效益方面相当，这支持在这种情况下尽可能广泛地使用ACE抑制剂。有证据表明，在这种情况下以及在许多其他情况下，ACE抑制剂的使用仍然不足。
